CLINICAL_TRIALS
trial_result
· 2020-03-17
Clinical Trial Update: A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease [Phase 2]
Summary
Phase 2 study evaluating CF102 for non-alcoholic steatohepatitis (NASH) has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Can-Fite BioPharma | Conditions: Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Status: COMPLETED